Quick Read – ABT has raised its dividend for 54 straight years, now yielding 2.8%, with four diversified segments delivering 7.8% revenue growth in Q1 2026. – FreeStyle Libre’s $2 billion quarterly revenue and the $21 billion Exact Sciences acquisition deepen Abbott’s moat in…
abetes and cancer diagnostics. – At $91, down 31% over the past year and well below the $117 analyst target, ABT offers a discounted entry into a proven compounder. – Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Abbott Laboratories didn’t make the cut. Grab the names FREE today
Abbott Laboratories (NYSE:ABT) is a stock with characteristics suited to multi-decade ownership, because its four-segment healthcare engine, 54 consecutive years of dividend increases, and recession-resistant end markets give a retirement-focused portfolio something rare: cash compounding that does not require monitoring. Pillar One: Durability Built Into the Business Model Abbott’s revenue flows from four distinct segments spanning multiple geographies and therapeutic areas, and the latest quarter shows why that matters. In Q1 2026, Medical Devices delivered $5.54 billion (+13.2% YoY), Diagnostics added $2.18 billion (+6.1%), Established Pharmaceuticals grew +13.2% in emerging markets, and Nutrition shrank 6.0%.
Three segments offset the weak one, and total revenue still grew 7.8% to $11.16 billion, exactly the four-headed structure that absorbs localized blows while sustaining cash flow. The moat keeps widening. The $21 billion Exact Sciences acquisition closed March 23, 2026, adding Cologuard and Cancerguard to the diagnostics arsenal.